Jieming QU

Company snapshot

Jieming QU is a pharma organization headquartered in CN. Primary therapeutic focus areas include 2019-nCoV. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: approved (1).

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Jieming QU. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Jieming QU.

1. May 26, 2026 Clinical update

   Arbidol — Approved

View all clinical trial activity →

• What is Jieming QU?

  Jieming QU is a pharma organization headquartered in CN. Primary therapeutic focus areas include 2019-nCoV. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline p

• Is Jieming QU publicly traded?

  Jieming QU appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Jieming QU develop or market?

  We link 1 drug profile(s) where Jieming QU is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/jieming-qu#company-drugs.

• What are the latest developments for Jieming QU?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Jieming QU focus on?

  Jieming QU focuses on 2019-nCoV based on our analysis of their pipeline programs and drug development activities.